Baird Maintains Neutral on Cogent Biosciences, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty maintains a Neutral rating on Cogent Biosciences (NASDAQ:COGT) and raises the price target from $8 to $10.
September 05, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Joel Beatty has maintained a Neutral rating on Cogent Biosciences while increasing the price target from $8 to $10, indicating a positive outlook.
The increase in the price target from $8 to $10 suggests a positive outlook for Cogent Biosciences, which could lead to a short-term increase in stock price. However, the Neutral rating indicates that the analyst does not see a strong buy opportunity, balancing the impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100